Menorrhagia: Treatment options

Thrombosis Research

Volumn 123, Issue SUPPL. 2, 2009, Pages

  Kadir, Rezan A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEMALE; HUMAN; MENORRHAGIA;

FEMALE; HUMANS; MENORRHAGIA;

EID: 65549166711     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70005-2     Document Type: Article

References (68)

1. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstet Gynecol 2001 Nov; 98(5 Pt 1):806-14.
2. Warner PE, Critchley HO, Lumsden MA, Campbell- Brown M, Douglas A, Murray GD. Menorrhagia I: Measured blood loss, clinical features, and outcome in women with heavy periods: A survey with follow-up data. Am J Obstet Gynecol 2004 May;190(5):1216 23.
3. Lethaby A, Augood C, Duckitt K. Nonsteroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 1998: CD000400.
4. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979;579(1):142 54.
5. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev (Online) 2000;(4): CD000249.
6. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev (Online) 2000;(4): CD000249.
7. Andersson L, Nilsson IM, Nilehn JE, Hedner U, Granstrand B, Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 1965;2(3): 230 47.
8. Rybo G. Tranexamic acid therapy effective treatment in heavy menstrual bleeding: Clinical update on safety. Ther Adv 1991;4:1-8.
9. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86(2):714-5.
10. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339(4):245 53.
11. Edlund M, Andersson K, Rybo G, Lindoff C, ̊Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995;102(11):913-7.
12. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73(3):274-7.
13. Cash JD, Gader AM, da Costa J. Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, 1-desamino-8-Darginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974;27(2):363-4.
14. Mannucci PM, ̊Aberg M, Nilsson IM, Robertsson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30: 81-93.
15. Sakariassen KS, Cattaneo M, vd BA, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984 Jul;64(1):229 36.
16. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996 Nov;76(5):692-6.
17. Leissinger C, Becton D, Cornell Jr C, Cox GJ. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001 May;7(3):258 66.
18. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: A randomized placebocontrolled crossover study. Haemophilia 2002 Nov;8(6): 787-93.
19. Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002;13(3):225-31.
20. Kouides P, Heit JA, Philiupp CS, Stein SF, Lukes AS, Byams VR, et al. A multi-site, prospective cross-over study of intranasal desmopressin and oral tranexamic acid in women with menorrhagia and abnormal laboratory hemostasis. ASH Annual Meeting Abstracts, Blood 2007; 110:711.
21. Mercorio F, De Simone R, Di Carlo C, Bifulco G, Tessitore G, Di Spiezio Sardo A, et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: A pilot study. Hum reprod (Oxford) 2003;18(11):2319-22.
22. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: A case report and review of 40 patients. Haemophilia 2000 Jan;6(1):11-4.
23. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J 1996 Sep 7;313(7057):579-82.
24. National Institute for Health and Clinical Excellence. Heavy menstrual bleeding, NICE clinical guideline 44. Developed by the National Collaborating Centre for Women's and Children's Health; 2007.
25. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev (Online) 2000;(2): CD002126.
26. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: A systematic review. Br J Obstet Gynaecol 2001 Jan;108(1):74-86.
27. Andersson K. The levonorgestrel intrauterine system: More than a contraceptive. Eur J Contracept Reprod Health Care 2001;6(Suppl 1):15-22.
28. Backman T, Huhtala S, Tuominen J, Luoto R, Erkkola R, Blom T, et al. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: An epidemiological survey in Finland. Eur J Contracept Reprod Health Care 2001;6(Suppl 1):23-6.
29. Mansour D. Modern management of abnormal uterine bleeding: The levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol 2007 Dec;21(6):1007-21.
30. Mansour D. Modern management of abnormal uterine bleeding: The levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol 2007 Dec;21(6):1007-21.
31. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br J Obstet Gynaecol 2004 Dec; 111(12):1425-8.
32. Kouides P, Phatak P, Sham RL, Braggins C, Andrew C, Howard F. The efficacy and safety of the levonorgestrel intrauterine device (Mirena) for bleeding disorder-related menorrhagia in an American cohort. Haemophilia 2006; 12:146. Abstract.
33. Chi C, Chase A, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of menorrhagia in women with inherited bleeding disorders: Longterm follow-up. Thromb Res 2007;119(Suppl 1):S101. Abstract.
34. World Health Organization (WHO). Medical eligibility criteria for contraceptive use. 2004.
35. Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 2005 Oct;193(4): 1361 3.
36. Pisoni CN CMKMHB. Treatment of menorrhagia associated with oral anticoagulation: Efficacy of levonorgestrel releasing intrauterine device. Thromb Res 2005;115:121. Abstract.
37. Ibraheim M, Ikomi A. An evaluation of troublesome intermenstrual bleeding in menorrhagic users of the LNG-IUS. J Obstet Gynaecol 2005 May;25(4):384-5.
38. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999 Sep;78(8):716-21.
39. Inki P, Hurskainen R, Palo P, Ekholm E, Grenman S, Kivela A, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol 2002 Oct;20(4):381-5.
40. Mansour D. Modern management of abnormal uterine bleeding: The levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol 2007 Dec;21(6):1007-21.
41. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust NZ J Obstet Gynaecol 1991;31(1):66 70.
42. Foster PA; on behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: Results of an international survey. Thromb Haemost 1995 Aug;74(2):784 90.
43. Jarvis RR, Olsen ME. Type I von Willebrand's disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002 May;99(5 Pt 2):887-8.
44. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial. J Am Med Assoc 2001 May 9;285(18):2347 54.
45. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002 Mar;186(3):389 95.
46. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001;86(1):112 23.
47. Archer DF. Menstrual-cycle-related symptoms: A review of the rationale for continuous use of oral contraceptives. Contraception 2006;74(5):359 66.
48. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev (Online) 2005;(3): CD004695.
49. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998;105(6):592-8.
50. American College of Obstetricians and Gynecologists. Management of anovulatory bleeding. Washington, DC: ACOG 2000. ACOG practice bulletin no. 14 [online]. Available from URL: Http://www.acog.org/publications/educational- bulletins/pb14.cfm.
51. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991;98(11): 1155-9.
52. Thomas EJ. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. Br J Obstet Gynaecol 1996 Oct;103(Suppl 14):18-21.
53. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol 1989; 96(7):840-4.
54. Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev (Online) 2007;(3): CD001017.
55. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev (Online) 2006;(2): CD003855.
56. Kuppermann M, Varner RE, Summitt Jr RL, Learman LA, Ireland C, Vittinghoff E, et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: The medicine or surgery (Ms) randomized trial. J Am Med Assoc 2004 Mar 24;291(12): 1447 55.
57. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: A randomised trial. Lancet 2001 Jan 27;357(9252):273-7.
58. Spilsbury K, Hammond I, Bulsara M, Semmens B. Morbidity outcomes of 78 577 hysterectomies for benign reasons over 23 years. Br J Obstet Gynaecol 2008;115:1473 83.
59. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: A systematic review. Br J Obstet Gynaecol 2004 Jul;111(7): 734 40.
60. Philipp CS, Dilley A, Miller CH, Evatt B, Baranwal A, Schwartz R, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1(3):477-84.
61. Lukes AS, Kouides PA. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: Clinical outcomes in the medicine or surgery trial. Obstet Gynecol 2004 Oct;104(4):864-5.
62. Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, et al. Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004 May;10(3):218-31.
63. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003;9:1 23.
64. Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 1999;(2): CD000329.
65. Istre O, Langebrekke A. Repeat hysteroscopic surgery reduces the hysterectomy rate after endometrial and myoma resection. J Am Assoc Gynecol Laparosc 2003 May;10(2):247 51.
66. Lethaby A, Hickey M. Endometrial destruction techniques for heavy menstrual bleeding: A Cochrane review. Hum Reprod (Oxford) 2002 Nov;17(11):2795 806.
67. Pugh CP, Crane JM, Hogan TG. Successful intrauterine pregnancy after endometrial ablation. J Am Assoc Gynecol Laparosc 2000 Aug;7(3):391-4.
68. Hare AA, Olah KS. Pregnancy following endometrial ablation: A review article. J Obstet Gynaecol 2005 Feb; 25(2):108 14.